IDEAYA Biosciences’ Post

IDEAYA Announces Pricing of Public Offering: https://lnkd.in/gvHKGftk

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants: https://lnkd.in/g95cKRSf

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer: https://lnkd.in/gnjZ4A94

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024: https://lnkd.in/gFxJayuU

IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://lnkd.in/grQHKRbP

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer: https://lnkd.in/gWX_6n3z

IDEAYA Announces Clinical Program Updates for IDE397, a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors: https://lnkd.in/gAKGVgiG

We are thrilled to announce our 5-year anniversary of being listed on NASDAQ. Thank you to our employees, patients we serve, collaboration partners and shareholders for being part of our journey to deliver innovative precision medicine therapies for cancer patients!

IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study: https://lnkd.in/dDVUhDZu

Yujiro Hata, President and CEO of IDEAYA Biosciences, discusses the potential of precision medicine oncology in the Pathfinders Podcast hosted by Joseph Coletti of RBC Capital Markets: https://lnkd.in/gfb7Wr7j